Insider · CIK 0001843508
Bob Holmen
Files at FTH (Faeth Therapeutics, Inc.). First filing -, latest -.
In brief
Bob Holmen files SEC Form 4 as director at FTH (Faeth Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Bob Holmen has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | FTH Faeth Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +12,500 | $0.00 | $0 | 12,500 | Jun 12, 2026 |
| May 21, 2025 | FTH Faeth Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +19,000 | $0.00 | $0 | 19,000 | May 23, 2025 |
Questions about Bob Holmen
Answered from the filings on this page, as of the latest one.
Is Bob Holmen buying or selling?
Bob Holmen has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Bob Holmen's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Bob Holmen has 0.
Where does Bob Holmen file Form 4?
Bob Holmen has filed Form 4 at FTH (Faeth Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.